Navigation Links
SCOLR Pharma, Inc. Retains Nicholas Hall & Company
Date:2/25/2011

BOTHELL, Wash., Feb. 25, 2011 /PRNewswire/ -- SCOLR Pharma, Inc. (OTC Bulletin Board: SCLR) today announced that it has retained Nicholas Hall & Company, a company providing complete support services to the global consumer healthcare industry, to introduce SCOLR to pharmaceutical companies, distributors and retailers that are interested in utilizing the Company's proprietary technology to develop OTC or prescription pharmaceutical or nutritional products.  

With more than 35 years' experience of strategic planning, market analysis and product placement, Nicholas Hall & Company, (www.nicholashall.com), possesses detailed knowledge of the consumer healthcare market worldwide.  

Stephen J. Turner, SCOLR Pharma's President and CEO, said, "Nicholas Hall & Company has a long and successful track record of assisting specialty pharma companies with their partnering and marketing strategy.  We believe their deep relationship with many of the world's leading pharmaceutical and over-the-counter (OTC) consumer products companies will be very valuable to SCOLR as we seek to partner and expand the utilization of our technology in OTC and prescription products."

About SCOLR Pharma:

Based in Bothell, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company focused on applying its formulation expertise and patented CDT platforms to develop novel prescription pharmaceutical, over-the-counter, and nutritional products. SCOLR's CDT drug delivery platforms are based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425-368-1050 or visit http://www.scolr.com/.

Forward looking statements:

This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the anticipated value of services to be provided by Nicholas Hall & Company, and the possibility of transactions involving the use of SCOLR's proprietary technology.  These forward-looking statements involve risks and uncertainties, including activities, events or developments that SCOLR expects, believes or  anticipates will or may occur in the future.  A number of factors could  cause actual results to differ from those indicated in the forward-looking statements, including the willingness of such of third parties to partner with SCOLR on acceptable terms, or at all, competition from larger and better funded pharmaceutical companies, SCOLR's ability to manage its liquidity and obtain financing necessary to continue its operations and, global economic conditions. Additional assumptions, risks and uncertainties related to SCOLR's business are described in detail in its registration statements, reports and other filings with the Securities and Exchange Commission, including the "Risk Factors" set forth in its Annual Report on Form 10-K, as supplemented by its quarterly reports on Form 10-Q.  Such filings are available on SCOLR's website or at www.sec.gov. You are cautioned that such statements are not guarantees of future performance and that actual result or developments may differ materially from those set forth in the forward-looking statements.  SCOLR undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstance.  


'/>"/>
SOURCE SCOLR Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. SCOLR Pharma, Inc. Common Stock to Begin Trading on OTC Bulletin Board and OTCQB Stock Market on January 13, 2011
2. SCOLR Pharma, Inc. Announces Intention to Voluntarily Delist From NYSE AMEX Exchange
3. SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results
4. SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director
5. SCOLR Pharma, Inc. Signs Agreement with The Emerson Group to Provide Sales Support for Nutritional & OTC Products
6. SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
7. SCOLR Pharma, Inc. Licenses Dietary Supplements
8. SCOLR Pharma, Inc. Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards
9. SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results
10. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
11. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... 17, 2017  BioDigital, Inc., creators of the ... their 3D body mapping technology with eClinicalWorks, a ... integration will be used to capture and present ... the human body. BioDigital pilots show using a ... also increasing the precision of clinical annotations compared ...
(Date:2/17/2017)... YORK , Feb. 17, 2017  Noble Capital ... on ESSA Pharma Inc. (Nasdaq: EPIX ). ... Research, Kumar Raja , PhD. ESSA ... for castration resistant prostate cancer (CRPC). Its lead compound ... blocks the amino-terminal domain of the androgen receptor, thereby ...
(Date:2/16/2017)... Research and Markets has announced the ... Technologies" report to their offering. ... Traditional medical devices include ... non-drug coated implantables, large endoscopes, needle based drug delivery, lab ... last two to three decades for the treatment and management ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... Smiles by Seese is a comprehensive ... NC. Dr. Brian Seese leads the practice as a skilled and highly credentialed dentist ... Smiles by Seese serves patients of all ages with excellence in general, restorative, and ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... allow for the electronic prescribing of controlled and non-controlled substances plus the ability ... of pharmacies in the United States now accept electronic prescriptions, according to the ...
(Date:2/17/2017)... ... February 17, 2017 , ... Empowering ... Francis' goals for each and every seminar, session and class she offers. ... five different brainwave tools which help energize creativity, focus mental functions, enhance athletic ...
(Date:2/17/2017)... ... February 17, 2017 , ... Access ... & Exhibition in Orlando, Fla., February 19-23. Visitors to the company’s booth (#1778) ... widely used electronic patient signatures solution in healthcare . , Since it ...
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica ... focusing on all facets of clinical trial planning and management. Pharmica discussed the ... and more. In addition, attendees stopping by Pharmica’s booth were able to demo ...
Breaking Medicine News(10 mins):